Etelcalcetide Research

Parshina EV, Gerasinchuk RP, Zemchenkov AY, Zulkarnaev AB

The prevalence of SHPT depends on control strategy and target level of PTH. There is insufficient data for a justified choice of goals and strategy for the SHPT correction.A retrospective, multicenter, cohort study was conducted to assess the ethelcalcetide efficacy after six months in real world...

Okamoto H, Goto S, Nose Y, Okamoto H, Fujii H

Calcimimetics such as etelcalcetide (ET) are used to manage secondary hyperparathyroidism patients with chronic kidney disease (CKD) on dialysis. While their cardiovascular benefits-including left ventricular hypertrophy (LVH) suppression-are recognized, the underlying mechanisms remain unclear. ...

Marn Pernat A, Pajek J, Buturović-Ponikvar J

Hypocalcemia is a common and clinically significant side effect of etelcalcetide therapy. The aim of this study was to evaluate the utility of ionized calcium (iCa) measurements with a point-of-care ionometer compared to albumin-corrected total calcium and to assess the incidence of hypocalcemia ...

Sato E, Urata M, Sato S, Ono T, Degawa M, Lu H et al.

No English-language research papers have reported on the clinical use of upacicalcet, a novel intravenous calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Therefore, this study aimed to investigate the outcomes of switching from etelcalcetide ...

Zou C, Wang X, Huang R, Hu H

The real-world safety of etelcalcetide in the treatment of dialysis-related secondary hyperparathyroidism (SHPT) was evaluated by analyzing associated adverse events (AEs) and assessing their clinical significance.Data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAE...

Nakazawa R, Onozaki A, Akiyama K, Uchino T, Azuma N

Secondary hyperparathyroidism (SHPT) is a common and serious complication in patients on hemodialysis (HD), leading to significant morbidity and mortality. Parathyroidectomy (PTx) is an established treatment for refractory SHPT, but many patients refuse this surgical option. This study evaluates ...

Zhou X, Li Y, Yang Y, Wei L, Wang C, Xu J et al.

Dietary polysaccharides have long been recognized for their capacity to modulate gut microbiota composition and metabolic activities, making them promising resources for functional food development. In this study, we investigated the effects of Poria cocos (P. cocos) polysaccharides on the struct...

Yuan M, Ma T, Fan Z, Li J, Zhang S

The calcium-sensing receptor (CaSR), a key member of the family C G protein-coupled receptors (GPCRs), plays a crucial role in regulating calcium homeostasis and parathyroid hormone (PTH) secretion. It responds to various physiological ligands, including calcium ions and amino acids, activating m...

Zhang D, Cai Y, Sun Y, Zeng P, Wang W, Wang W et al.

This study's main goal was to closely monitor and record adverse events (AEs) related to the medication Etelcalcetide, which is used to treat secondary hyperparathyroidism (SHPT, which is defined as elevated parathyroid hormone (PTH) levels in response to abnormalities in the calcium, phosphate, ...

Freitas P, Pereira L

The impact of etelcalcetide on patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) has been studied since its introduction in 2016/2017. However, only a handful of studies reported clinically relevant outcomes. This narrative review aims to summarize the published ...

Henner DE, Drambarean B, Gerbeling TM, Kendrick JB, Kendrick WT, Koester-Wiedemann L et al.

Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD). Many recommendations in the Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder guidelines are supported by modest evidence and predate the approval of newer agents. Therefore,...

Wojtowicz D, Laham G, Forrester M, Del Valle E, Peñalba A, Filannino G et al.

Secondary hyperparathyroidism (sHPT) is a common complication in patients with chronic kidney disease (CKD). Recently, etelcalcetide (EC), an intravenous calcimimetic, has been introduced as a treatment. We evaluated the efficacy of EC in treating sHPT.We conducted a multicenter, observational, r...

Du W, Boisen IM, Rahman SN, Poulsen NN, Mathiesen JM, Blomberg Jensen M et al.

The human calcium-sensing receptor (CaSR) plays a key role in calcium homeostasis, and most identified CASR variants are associated with hypercalcemic and hypocalcemic disorders.Here we characterized the pharmacological implications of 5 heterozygous CASR variants from individuals with familial h...

Fusaro M, Aghi A, Marino C, Mallamaci F, Plebani M, Zaninotto M et al.

Background/Objectives: Chronic kidney disease and mineral bone disorders (CKD-MBD) are frequently associated with an increased risk of both vascular calcifications (VCs) and bone fractures (BFs). The complex pathogenesis of VCs and BFs involves various factors such as calcium overload, phosphate ...

Negri AL, Bover J, Vervloet M, Cozzolino M

Secondary hyperparathyroidism is one of the most frequent metabolic abnormalities found in patients with chronic kidney disease. The calcium-sensing receptor senses extracellular calcium and is the principal regulator of parathyroid hormone secretion. Cloning of the calcium-sensing receptor led t...

Karaboyas A, Zhao J, Ma J, Moore C, Saleem N, Martin KJ et al.

After incorporation into the bundle in 2021, etelcalcetide use decreased substantially, reflecting financial incentives to restrict access. Etelcalcetide discontinuers had a swift and sustained increase in parathyroid hormone and loss of secondary hyperparathyroidism control, despite most switchi...

Chiu HW, Lu KC, Lin YC, Hou YC, Liao MT, Chen YJ et al.

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a multifaceted clinical syndrome characterized by mineral imbalances, abnormalities in bone metabolism, chronic inflammation and vascular calcification. Etelcalcetide, a second-generation intravenous calcimimetic agent, has been approv...

Delaey P, Devresse A, Morelle J, Faitatzidou D, Iriarte M, Kanaan N et al.

Etelcalcetide is an i.v. calcimimetic agent, effectively reducing parathyroid hormone levels in patients on maintenance hemodialysis (HD). The clinical impact of discontinuing etelcalcetide at the time of kidney transplantation is unknown.We retrospectively reviewed all patients on HD meeting pre...

Liu X, Liu Y, Zheng P, Xie X, Li Z, Yang R et al.

Active vitamin D analogs and calcimimetic agents are primary drugs for patients with secondary hyperparathyroidism. Due to the different pharmacological mechanisms, they have different effects on the level of parathyroid hormone, serum calcium, phosphorus, and bone turnover biomarkers. This study...

Matarage Don NNJ, Padmavathi R, Khasro TD, Zaman MRU, Ji HF, Ram JL et al.

The calcium-sensing receptor (CaSR), abundantly expressed in the parathyroid gland and kidney, plays a central role in calcium homeostasis. In addition, CaSR exerts multimodal roles, including inflammation, muscle contraction, and bone remodeling, in other organs and tissues. The diverse function...